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they demonstrate that aft er gentamicin 
initiates the cell elimination process by 
targeting mitochondria, the result (cell 
death), after the  ‘ point of no return ’ 
(mitochondrial permeabilization 2 ) is 
passed, is reali zed through a number of 
diff erent elements (enhanced ROS pro-
duction, mitochondrial cytochrome  c 
loss, NAD pool depletion) to guarantee 
the outcome. Th e mechanism by which 
metformin interferes with mitochondrial 
permeabilization in this case remains to 
be resolved; this understanding should 
facilitate the development of better 
ways to protect against unwanted cell 
death as a result of (unintended) mito-
chondrial injury. 
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 Glucocorticoids (GCs), introduced 
60 years ago for the treatment of infl am-
matory and autoimmune disorders, 
remain a mainstay of therapy for various 
renal diseases. Indeed, the rate of mortal-
ity from systemic lupus erythematosus fell 
precipitously following the introduction 
of steroids in the early 1950s. Remarkably, 
these agents remain a primary therapy for 
lupus nephritis. Steroids are limited by the 
wide range of untoward eff ects, including 
Cushing ’ s syndrome, dyslipidemia, hyper-
tension, pancreatitis, immunosuppres-
sion, bone necrosis and osteoporosis, 
muscle atrophy, cataracts, and hypogo-
nadism. 1 Consequently, the identifi cation 
of GCs with greater selectivity and spe-
cifi city has been a Holy Grail for many 
pharmacologists. 
 It is disappointing, then, that despite 
extensive eff orts expended in pursuit of 
this goal, very limited progress has been 
made in the development of such agents. 
Th e absence of progress is understand-
able as greater insight has been gained 
in discerning the anti-inflammatory 
mechanisms of action of GCs. One of the 
greatest hurdles in the development of 
more selective anti-infl ammatory agents 
lies in the GC receptor itself. Th e levels of 
the receptor protein are regulated in both 
tissue-specific and cell cycle-specific 
fashions. Additionally, several splice and 
translation variants of the protein have 
been identifi ed. 
 Th ere are three primary mechanisms of 
action of GCs: 2 direct cortisol – GC receptor 
DNA interactions; protein interference 
mechanisms secondary to the transcrip-
tion of gene products that interact with 
the cortisol – GC receptor complex; and 
nongenomic pathways, that is, the interac-
tion of GCs with membrane receptors and 
second messengers. Each of these mecha-
nisms has been well studied in exploring 
the anti-inflammatory mechanisms of 
GCs. Examples of GC-mediated infl am-
matory mechanisms include the inhibi-
tion of prostaglandin production by the 
repression of cyclooxygenase-2; the induc-
tion of MAPK phosphatase I, leading to 
the dephosphorylation and inactivation 
of Jun N-terminal kinase; and the direct 
physical interaction of the cortisol – GC 
receptor complex with nuclear factor-  B. 
Th e last mechanism is particular impor-
tant because nuclear factor-  B induces 
the transcription of cyclooxygenase-2, as 
well as several cytokines, chemokines, and 
cell adhesion molecules. 
 Therefore, there are many levels at 
which the anti-infl ammatory eff ects of 
GCs can be understood, and many sites at 
which GC homologs could be designed to 
increase specifi city and potency. Examples 
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 Understanding the mechanisms of glucocorticoid-mediated inhibition 
of inflammation has been challenging. This is particularly true with 
regard to the development of drugs that mimic the anti-inflammatory 
benefits of steroids while avoiding the untoward metabolic effects. 
F ö rster  et al. report that the inhibition of stress-induced mesangial-cell 
apoptosis by dexamethasone is mediated by sphingosine-1-phosphate. 
These findings identify alternative pathways whereby the 
anti-inflammatory mechanisms of glucocorticoids can be probed. 
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include the targeting of receptor – ligand 
binding and the inhibition of transactiva-
tion or transrepression. Inhibitors of 
transactivation would in theory target GC 
receptor-mediated upregulated genes, of 
which only a limited number have been 
identifi ed. Transrepression appears to be 
the more common mechanism and 
involves the interference of the receptor 
with DNA-bound transcription factors. 
Th ese factors include CREB, nuclear fac-
tor-  B, NFAT, STAT, and IRF3. These 
transcription factors in turn regulate the 
transcription of a large number of infl am-
matory proteins, including interleukin 
(IL)-1  , IL-2, IL-4, IL-5, IL-6, IL-8, IL-12, 
IL-18, cyclooxygenase-2, E-selectin, 
inducible nitric oxide synthase, inter-
feron-  , tumor necrosis factor-  , intercel-
lular adhesion molecule, vascular cell 
adhesion molecule, and monocyte chemo-
attractant protein-1. A number of these 
mediators have been considered as targets 
for novel therapeutics, typically in the 
form of antibodies. As an alternative strat-
egy, one might explore whether all of the 
downstream mediators of GC actions have 
been identifi ed and characterized. 
 F ö rster and colleagues 3 (this issue) have 
posed that question. Th ey report that the 
induction of apoptosis in mesangial cells 
is rescued by treatment with dexametha-
sone and that the protective eff ect of dex-
amethasone occurs through the formation 
of sphingosine-1-phosphate. In support 
of this observation, they observed that 
dexamethasone upregulated the tran-
scription of the precursor enzymes sphin-
gosine kinase and neutral ceramidase. 
Th is eff ect was blocked in the presence of 
a sphingosine kinase inhibitor or in cells 
lacking a functional sphingosine kinase. 
Th ese experiments focused on a simple 
but fundamental pathway of sphingolipid 
metabolism: the metabolism of ceramide 
by the neutral ceramidase to form sphin-
gosine and sphingosine-1-phosphate. 
Because sphingosine is formed only from 
ceramide, the pathways coupling the 
ceramidase and sphingosine kinase are 
necessarily linked. Th ese fi ndings are sig-
nifi cant because they identify sphingoli-
pid signaling molecules as potential 
mediators of some of the anti-infl amma-
tory eff ects of GCs. Sphingolipids are a 
class of lipids characterized by the pres-
ence of a long-chain lipophilic amine. 
Th ese lipids were named by their disco-
verer, J.L.W. Th udicum, in reference to 
the riddle of the sphinx because of their 
enigmatic nature. Th e implication of the 
work of F ö rster  et al. 3 is that the target-
ing of sphingolipid metabolites specifi -
cally may result in anti-infl ammatory 
benefi ts with the avoidance of untoward 
side eff ects seen with GCs. Support for 
this strategy can be found in a large 
number of studies implicating specifi c 
sphingolipids as mediators of immune 
function. Th ese include not only cera-
mide and sphingosine-1-phosphate, but 
ceramide-1-phosphate, free long-chain 
bases such as sphingosine, and a large 
number of ceramide-based glycosphin-
golipids ( Figure 1 ). 
 However, establishing the merits of this 
strategy will require significant effort. 
First, because ceramide and sphingosine-
1-phosphate are not the only sphingo-
lipids implicated in signaling and other 
cellular functions, proof-of-principle 
experiments designed to establish a link 
between the anti-infl ammatory eff ects of 
GCs and changes in either ceramide or 
sphingosine-1-phosphate will need to 
more comprehensively account for other 
bioactive sphingolipids. Th e fl ux of sphin-
golipids through the myriad of anabolic 
and catabolic pathways is rapid and 
dependent on multiple factors. 4 These 
include substrate availability, subcellular 
localization, lipid recycling, and feedback 
inhibition of synthetic enzymes, to name 
but a few. Second, the action of candidate 
bioactive sphingolipids will need to be 
better understood. Sphingosine-1-phos-
phate, for example, acts within cells as a 
second messenger and extracellularly as a 
ligand for one of several sphingosine-1-
phosphate receptors. 5 Despite more than 
20 years of work, the cellular targets for 
ceramide remain less well established, but 
include, for example, protein phosphatase 
2A. Inhibition of this enzyme has been 
demonstrated to have secondary eff ects 
on a variety of receptor tyrosine kinases. 
Th ird, because the eff ects of GCs on pro-
liferation and apoptosis are cell specifi c, it 
will be important to determine whether 
the sphingolipid eff ects are cell specifi c as 
well. Interestingly, ceramide has been 
reported to have both proapoptotic and 
pro-proliferative eff ects. Whether this is 
coincidental or refl ects a biological nexus 
between GCs and ceramide should be 
actively explored. 
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3-keto-sphinganine
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Dihydroceramide
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• inhibition of neutrophil
  oxidant formation
• lymphocyte apoptosis
Ceramide-1-phosphate
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• splenomegaly
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Gangliosides
• CNS inflammation
 Figure 1  |  Simple anabolic pathways governing sphingolipid formation and major bioactive 
sphingolipids. Bulleted items are examples of associations between major sphingolipids and 
inflammatory conditions that characterize classic clinical disorders. These disorders include 
Gaucher ’ s disease (glucosylceramide); Fabry ’ s disease and hemolytic uremic syndrome 
(globotriaosylceramide); Niemann – Pick disease (sphingomyelin); Farber ’ s disease (ceramide); and 
brown recluse spider bites (ceramide-1-phosphate). CNS, central nervous system. 
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 Nevertheless, both sphingolipid mime-
tics and small-molecule inhibitors of 
sphingolipid-metabolizing enzymes have 
already been developed, lending credence 
to the view that these are  ‘ druggable ’ 
pathways. Th ese include FTY720 (fi ngoli-
mod) and Genz-112638 (eliglustat). 
FTY720 is a structural homolog of myri-
ocin, a fungal product and sphingosine 
analog. FTY720 is phosphorylated  in vivo 
by sphingosine kinase 2 and subsequently 
binds to sphingosine-1-phosphate recep-
tors or inhibits intracellular targets such 
as cPLA2 and ceramide synthase. The 
immunosuppressive eff ects of FTY720 are 
believed to be secondary to the prevention 
of the egress of lymphocytes from lymph 
nodes. 6 FTY720 has been reported to 
reduce the frequency of relapses in multi-
ple sclerosis. A regulatory fi ling seeking 
approval for the treatment of multiple 
sclerosis was recently announced. The 
development of FTY720 was halted when 
the compound was found to be no more 
eff ective than conventional therapy in the 
prevention of organ rejection. Genz-
112638 is a highly selective inhibitor of 
glucosylceramide synthase. This com-
pound blocks the glycosylation of cera-
mide to form glucosylceramide, the base 
cerebroside for more than 80 % of mam-
malian glycosphingolipids. Recent phase 
2 trials of the use of Genz-112638 for the 
treatment of type I Gaucher ’ s disease have 
reported that this oral compound is com-
parable to enzyme replacement therapy in 
the reduction of spleen size and the 
improvement of anemia and thrombo-
cytopenia. 7 Phase 3 trials are currently in 
progress. Proof-of-concept studies have 
also been conducted with this class of 
compounds in mouse models of Fabry ’ s 
disease, suggesting that inhibition of gly-
cosphingolipids with Genz-112638, 
including globotriaosylceramide, will also 
provide an alternative treatment strategy 
for this renal disease. 
 Th us sphingolipid biology off ers a new 
window that may not only shed light on 
the old problem of dissociating the anti-
infl ammatory eff ects of GC from its secon-
dary metabolic actions, but may off er new 
strategies for the development of novel 
therapeutics. Although it remains to be 
proven whether specific sphingolipids 
mediate infl ammatory and autoimmune 
diseases of the kidney, these metabolites 
have already been demonstrated to medi-
ate inflammatory and proliferative 
responses in a variety of other organs and 
pathological settings. For clinicians and 
investigators focused on renal infl amma-
tory disease, these pathways pose new rid-
dles to be solved. 
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 Hyperphosphatemia has been linked 
with increased mortality and cardio-
vascular disease in chronic kidney 
disease (CKD). Although control of 
serum phosphorus levels can be obtained 
with prolonged nocturnal dialysis by 
itself, 1 the vast majority of patients receiv-
ing currently recommended dialysis 
regimens require the use of phosphate-
binding agents. 
 Th e ideal phosphate binder has yet to be 
identifi ed, and today there are multiple 
options for prescribing such agents. Nearly 
40 years ago, aluminum-based binders 
were introduced, and although eff ective, 
chronic administration led to signifi cant 
tissue accumulation and to the develop-
ment of encephalopathy, osteomalacia, 
myopathy, and microcytic anemia. Such 
compounds were replaced by calcium-
based binders, which are both eff ective 
and inexpensive. However, the success of 
calcium-based binders has been tempered 
by evidence that their use leads to higher 
serum calcium levels, more frequent epi-
sodes of hypercalcemia, adynamic bone 
disease, diminished bone buff er capacity, 
and vascular calcifi cations. 2 – 4 
 Ironing out the 
phosphorus problem 
 Joshua J.  Zaritsky 1 and  Isidro B.  Salusky 1 
 Control of serum phosphorus remains a vexing problem in chronic 
kidney disease. Although novel dialysis regimens may provide excellent 
phosphorus control, phosphate binders remain necessary for most 
dialysis patients. Block  et al. present a phase I clinical trial examining the 
safety and efficacy of SBR759, a novel non-calcium, iron-based phosphate 
binder. Although the risks of iron accumulation and hypocalcemia must 
be addressed, this phosphate binder appears to be well tolerated and 
effective and offers a powder-based formulation. 
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